We have located links that may give you full text access.
Acetylcholine receptor antibodies in patients with Graves' ophthalmopathy.
Journal of Neuro-ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society 1995 September
OBJECTIVES: To determine the frequency and clinical correlates of acetylcholine receptor (AChR) antibody seropositivity in patients with Graves' ophthalmopathy.
MATERIALS AND METHODS: Fifty consecutive new patients with Graves' ophthalmopathy diagnosed in an outpatient neuro-ophthalmology practice underwent determination of AChR-binding antibodies. Clinical and biochemical thyroid variables were compared between seropositive and seronegative patients. Clinical variables included age, sex, thyroid disorder, and duration and course of illness. Biochemical variables included thyroid hormone levels and thyroid antibodies. Seropositive patients were followed clinically to identify signs of myasthenia gravis.
RESULTS: Four of 50 (8%) patients had definitely elevated levels of AChR-binding antibodies. No obvious differences existed between the seropositive and seronegative groups in regards to age, sex, underlying thyroid disorder, biochemical thyroid state, presence of thyroid antibodies, or duration and course of their disease. None of the four seropositive patients developed signs of myasthenia gravis during the median follow-up period of 4.5 years.
CONCLUSION: AChR-binding antibody seropositivity occurs in a small proportion of patients with Graves' ophthalmopathy but, by itself, does not necessarily identify an individual with concurrent myasthenia gravis or an individual at risk to develop myasthenia gravis.
MATERIALS AND METHODS: Fifty consecutive new patients with Graves' ophthalmopathy diagnosed in an outpatient neuro-ophthalmology practice underwent determination of AChR-binding antibodies. Clinical and biochemical thyroid variables were compared between seropositive and seronegative patients. Clinical variables included age, sex, thyroid disorder, and duration and course of illness. Biochemical variables included thyroid hormone levels and thyroid antibodies. Seropositive patients were followed clinically to identify signs of myasthenia gravis.
RESULTS: Four of 50 (8%) patients had definitely elevated levels of AChR-binding antibodies. No obvious differences existed between the seropositive and seronegative groups in regards to age, sex, underlying thyroid disorder, biochemical thyroid state, presence of thyroid antibodies, or duration and course of their disease. None of the four seropositive patients developed signs of myasthenia gravis during the median follow-up period of 4.5 years.
CONCLUSION: AChR-binding antibody seropositivity occurs in a small proportion of patients with Graves' ophthalmopathy but, by itself, does not necessarily identify an individual with concurrent myasthenia gravis or an individual at risk to develop myasthenia gravis.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
The Effect of Albumin Administration in Critically Ill Patients: A Retrospective Single-Center Analysis.Critical Care Medicine 2024 Februrary 8
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app